Longitudinal analysis of safety and medication adherence of patients in the Fingolimod patient support program: a real-world observational study.
Fiche du document
18 février 2021
- doi: 10.1038/s41598-021-83220-1
- issn: 2045-2322
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1038/s41598-021-83220-1
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/33603005
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2045-2322
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_8A087AFA31EC1
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Semiology (Medicine) Diseases--Symptoms Symptomatology Signs, Clinical Clinical signs Semiology Symptomology Signs and symptoms Disease symptoms Patient adherence Compliance of patients Adherence of patients Patient cooperation Cooperation of patients Sick--Cooperation Sick--Compliance with regimen Treatment compliance Use of Methods of analysis Analysis and chemistry Analytical methods Chemical analysis Analysis methods Analysis and examinationCiter ce document
A. Bourdin et al., « Longitudinal analysis of safety and medication adherence of patients in the Fingolimod patient support program: a real-world observational study. », Serveur académique Lausannois, ID : 10.1038/s41598-021-83220-1
Métriques
Partage / Export
Résumé
The Fingolimod Patient Support Program (F-PSP) is an interprofessional specialty pharmacy service designed to ensure responsible use of fingolimod by promoting patient safety and medication adherence. This study aims to evaluate the safety and medication adherence of patients who joined the F-PSP between 2013 and 2016. Sociodemographic and medical characteristics, patient safety data (patient-reported symptoms, discontinuations due to adverse events (AEs), repeated first-dose monitoring), and medication adherence (implementation, persistence, reasons for discontinuation, influence of covariates, barriers and facilitators) were described. Sixty-seven patients joined the F-PSP. Patients reported a high frequency of symptoms. Due to AEs, 7 patients discontinued fingolimod, 3 took therapeutic breaks, and 1 reduced the regimen temporarily. Three patients repeated the first-dose monitoring. Patients had a high medication adherence over the 18-month analysis period: implementation decreased from 98.8 to 93.7%, and fingolimod persistence was 83.2% at 18 months. The patients' level of education, professional situation, and living with child(ren) influenced implementation. Patients reported more facilitators of medication adherence than barriers. The F-PSP seems valuable for supporting individual patients (ensuring responsible use of fingolimod and inviting patients for shared-decision making) and public health (indirectly gathering real-world evidence).